JPH0337525B2 - - Google Patents

Info

Publication number
JPH0337525B2
JPH0337525B2 JP57195192A JP19519282A JPH0337525B2 JP H0337525 B2 JPH0337525 B2 JP H0337525B2 JP 57195192 A JP57195192 A JP 57195192A JP 19519282 A JP19519282 A JP 19519282A JP H0337525 B2 JPH0337525 B2 JP H0337525B2
Authority
JP
Japan
Prior art keywords
carnitine
acylcarnitine
improving agent
treatment
edema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP57195192A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5888312A (ja
Inventor
Kabaza Kuraujio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JPS5888312A publication Critical patent/JPS5888312A/ja
Publication of JPH0337525B2 publication Critical patent/JPH0337525B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP57195192A 1981-11-06 1982-11-05 カルニチンまたは低級アシルカルニチンからなる静脈疾患治療剤 Granted JPS5888312A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT49655/81A IT1142934B (it) 1981-11-06 1981-11-06 Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT49655A/81 1981-11-06

Publications (2)

Publication Number Publication Date
JPS5888312A JPS5888312A (ja) 1983-05-26
JPH0337525B2 true JPH0337525B2 (https=) 1991-06-05

Family

ID=11271255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57195192A Granted JPS5888312A (ja) 1981-11-06 1982-11-05 カルニチンまたは低級アシルカルニチンからなる静脈疾患治療剤

Country Status (3)

Country Link
US (1) US4415589A (https=)
JP (1) JPS5888312A (https=)
IT (1) IT1142934B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
US5641764A (en) * 1989-03-31 1997-06-24 Peter Maccallum Institute Halogenated DNA ligand radiosensitizers for cancer therapy
IT1231944B (it) * 1989-05-05 1992-01-16 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
DK0793962T3 (da) * 1996-03-04 2000-05-22 Sigma Tau Ind Farmaceuti Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
RU2245145C1 (ru) * 2003-10-01 2005-01-27 Российский государственный медицинский университет Средство нормализации агрегационных свойств тромбоцитов и эритроцитов и морфоденситометрических характеристик эритроцитов
KR101097006B1 (ko) * 2006-11-09 2011-12-20 미츠비시 레이온 가부시키가이샤 베타인의 제조 방법
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
EP2353596A1 (en) * 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
KR101758949B1 (ko) * 2010-04-09 2017-07-17 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 활성 성분으로 ｌ-카르니틴 또는 프로피오닐 ｌ-카르니틴을 포함하는, 만성 정맥 기능부전의 예방 또는 치료용 복합 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche

Also Published As

Publication number Publication date
US4415589A (en) 1983-11-15
JPS5888312A (ja) 1983-05-26
IT1142934B (it) 1986-10-15
IT8149655A0 (it) 1981-11-06

Similar Documents

Publication Publication Date Title
Freis et al. Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents
Carliner et al. Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia
JPH0337525B2 (https=)
US8343979B2 (en) Use of alkanoyl L-carnitine for the treatment of erectile dysfunction
TWI331920B (en) Unit dosage form for relieving or treating constipation in human patients
Young et al. Severe arteriospasm after use of ergotamine tartrate suppositories: report of a case
KR100244092B1 (ko) L-카르니틴 또는 아실l-카르니틴과 ace-억제제를 함유한 심장혈관질환치료용 약제조성물과 그 치료방법
Athanassiadis et al. Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure
JPS59116216A (ja) アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤
MEILMAN The management of hypertensive cardiovascular disease
ES2203115T3 (es) Composicion que comprende ketanserina y l-carnitina para el tratamiento del sindrome de dolor local cronico.
JP5923044B2 (ja) 活性成分としてｌ−カルニチンまたはプロピオニルｌ−カルニチンを含む慢性静脈不全の予防または治療のための併用組成物
Sandstead et al. Relief of Diabetic Pain of Neurocirculatory Origin by Oral Administration of Sodium Chloride
JPH02262519A (ja) 糖尿病性神経障害治療剤
RU2294204C1 (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
CN102349923B (zh) L-肉碱和葡萄糖治疗心血管疾病的应用
US6897239B1 (en) Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women
Hodge Guanoclor as an antihypertensive drug
MILLER et al. Oral bismuth therapy in dermatology
Botha A clinical trial of pempidine in the treatment of hypertension
Folb Drugs in Common Use
SCHNEIDER et al. HYPERYITAMINOSIS D
MXPA99011357A (en) Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps
JP2014172846A (ja) がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤